Understanding the immunopathogenesis of chronic hepatitis B virus: An Asian prospective

Journal of Gastroenterology and Hepatology (Australia)

Volumn 23, Issue 6, 2008, Pages 833-843

  Tan, Anthony Tanoto ^a   Koh, Sarene ^a   Goh, Vera ^a   Bertoletti, Antonio ^a,b  

^a AGENCY FOR SCIENCE   (Singapore)

^b ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

Adaptive immune response; Asian; Hepatitis B virus; Host and viral factors; Innate immunity

Indexed keywords

TRANSCRIPTION FACTOR FOXP3; VIRUS ANTIGEN;

ASIAN; CHRONIC HEPATITIS; DENDRITIC CELL; DISEASE TRANSMISSION; DNA POLYMORPHISM; HEPATITIS B; HEPATITIS B VIRUS; HEREDITY; HUMAN; IMMUNE RESPONSE; IMMUNOPATHOGENESIS; INNATE IMMUNITY; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; REVIEW;

EID: 44949180106     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/j.1440-1746.2008.05385.x     Document Type: Review

References (129)

1. Quintana-Murci L, Alcais A, Abel L, Casanova JL. Immunology in natura: clinical, epidemiological and evolutionary genetics of infectious diseases. Nat Immunol. 2007 8: 1165 71.
2. Merican I, Guan R, Amarapuka D et al. Chronic hepatitis B virus infection in Asian countries. J. Gastroenterol. Hepatol. 2000 15: 1356 61.
3. Thursz M. Host genetic factors influencing the outcome of hepatitis. J. Viral. Hepat. 1997 4: 215 20.
4. Chi-Jen Chu ASFL. Clinical significance of hepatitis B virus genotypes. Hepatology 2002 35: 1274 6.
5. Scott K, Fung ASFL. Hepatitis B virus genotypes: do they play a role in the outcome of HBV infection? Hepatology 2004 40: 790 2.
6. Kao J-H, Wu N-H, Chen P-J, Lai M-Y, Chen D-S. Hepatitis B genotypes and the response to interferon therapy. J. Hepatol. 2000 33: 998 1002.
7. Wai CT, Chu C-J, Hussain M, Lok ASF. HBV genotype B is associated with better response to interferon therapy in HBeAg(+) chronic hepatitis than genotype C. Hepatology 2002 36: 1425 30.
8. de Campos Lima PO, Gavioli R, Zhang QJ et al. HLA-A11 epitope loss isolates of Epstein-Barr virus from a highly A11+ population. Science 1993 260: 98 100.
9. Gaudieri S, Rauch A, Park LP et al. Evidence of viral adaptation to HLA class I-restricted immune pressure in chronic hepatitis C virus infection. J. Virol. 2006 80: 11094 104.
10. Moore CB, John M, James IR, Christiansen FT, Witt CS, Mallal SA. Evidence of HIV-1 adaptation to HLA-restricted immune responses at a population level. Science 2002 296: 1439 43.
11. Stevens C, Beasley R, Tsu J. Vertical transmission of hepatitis B antigen in Taiwan. N. Engl. J. Med. 1975 292: 771 4.
12. Whittle HC, McLauchlan K, Bradley AK et al. HBV infection in the gambia. Lancet 1983 2: 733.
13. Levy O. Innate immunity of the newborn: basic mechanisms and clinical correlates. Nat. Rev. Immunol. 2007 7: 379 90.
14. Roy CR, Mocarski ES. Pathogen subversion of cell-intrinsic innate immunity. Nat. Immunol. 2007 8: 1179 87.
15. Akira S, Uematsu S, Takeuchi O. Pathogen recognition and innate immunity. Cell 2006 124: 783 801.
16. Takaoka A, Wang Z, Choi MK et al. DAI (DLM-1/ZBP1) is a cytosolic DNA sensor and an activator of innate immune response. Nature 2007 448: 501 5.
17. Roggendorf M, Tolle TK. The woodchuck: an animal model for hepatitis B virus infection in man. Intervirology 1995 38: 100 12.
18. Webster G, Reignat S, Maini M et al. Incubation phase of acute Hepatitis B in man: dynamic of cellular immune mechanism. Hepatology 2000 32: 1117 24.
19. Webster G, Hallet R, Whalley S et al. Molecular epidemiology of a large outbreak of hepatitis B linked to autohaemoterapy. Lancet 2000 356: 379 84.
20. Wu J, Lu M, Meng Z et al. Toll-like receptor-mediated control of HBV replication by nonparenchymal liver cells in mice. Hepatology 2007 46: 1769 78.
21. Isogawa M, Robek MD, Furuichi Y, Chisari FV. Toll-like receptor signaling inhibits hepatitis B virus replication in vivo. J. Virol. 2005 79: 7269 72.
22. Yalcin K, Degertekin H, Yildiz F, Kilinc N. A severe hepatitis flare in an HBV-HCV coinfected patient during combination therapy with alpha-interferon and ribavirin. J. Gastroenterol. 2003 38: 796 800.
23. Lee J, Wu CC, Lee KJ et al. Activation of anti-hepatitis C virus responses via Toll-like receptor 7. Proc. Natl. Acad. Sci. USA 2006 103: 1828 33.
24. Wieland S, Thimme R, Purcell RH, Chisari FV. Genomic analysis of the host response to hepatitis B virus infection. Proc. Natl. Acad. Sci. USA 2004 101: 6669 74.
25. Wieland SF, Guidotti LG, Chisari FV. Intrahepatic induction of alpha/beta interferon eliminates viral RNA-containing capsids in hepatitis B virus transgenic mice. J. Virol. 2000 74: 4165 73.
26. McClary H, Koch R, Chisari FV, Guidotti LG. Relative sensitivity of hepatitis B virus and other hepatotropic viruses to the antiviral effects of cytokines. J. Virol. 2000 74: 2255 64.
27. Wieland S, Chisari FV. Stealth and cunning: Hepatitis B and Hepatitis C viruses. J. Virol. 2005 79: 9369 80.
28. Visvanathan K, Skinner NA, Thompson AJ et al. Regulation of Toll-like receptor-2 expression in chronic hepatitis B by the precore protein. Hepatology 2007 45: 102 10.
29. Ou R, Zhou S, Huang L, Moskophidis D. Critical role for alpha/beta and gamma interferons in persistence of lymphocytic choriomeningitis virus by clonal exhaustion of cytotoxic T cells. J. Virol. 2001 75: 8407 23.
30. Biron CA. Interferons alpha and beta as immune regulators - a new look. Immunity 2001 14: 661 4.
31. Bertoletti A, Ferrari C. Kinetics of the immune response during HBV and HCV infection. Hepatology 2003 38: 4 13.
32. Fong TL, Di Bisceglie AM, Biswas R et al. High levels of viral replication during acute hepatitis B infection predict progression to chronicity. J. Med. Virol. 1994 43: 155 8.
33. Korba BE, Cote PJ, Wells FV et al. Natural history of woodchuck hepatitis virus infections during the course of experimental viral infection: molecular virologic features of the liver and lymphoid tissues. J. Virol. 1989 63: 1360 70.
34. Berquist KR, Peterson JM, Murphy BL, Ebert JW, Maynard JE, Purcell RH. Hepatitis B antigens in serum and liver of chimpanzees acutely infected with hepatitis B virus. Infect Immun. 1975 12: 602 5.
35. Guidotti LG, Rochford R, Chung J, Shapiro M, Purcell R, Chisari FV. Viral clearance without destruction of infected cells during acute HBV infection. Science 1999 284: 825 9.
36. Thimme R, Wieland S, Steiger C et al. CD8 (+) T cells mediate viral clearance and disease pathogenesis during acute hepatitis B virus infection. J. Virol. 2003 77: 68 76.
37. Whalley SA, Murray JM, Brown D et al. Kinetics of acute hepatitis B virus infection in humans. J. Exp. Med. 2001 193: 847 54.
38. Jilbert A, Wu T, England J et al. Rapid resolution of duck hepatitis B virus infections occurs after massive hepatocellular involvment. J. Virol. 1992 66: 1377 88.
39. Kajino K, Jilbert AR, Saputelli J, Aldrich CE, Cullen J, Mason WS. Woodchuck hepatitis virus infections: very rapid recovery after prolonged viremia and infection of virtually every hepatocyte. J. Virol. 1994 68: 5792 803.
40. Thimme R, Bukh J, Spangenberg HC et al. Viral and immunological determinants of hepatitis C virus clearance, persistence and disease. Proc. Natl Acad. Sci. USA 2002 99: 15661 8.
41. Nakamura I, Nupp JT, Cowlen M et al. Pathogenesis of experimental neonatal woodchuck hepatitis virus infection: chronicity as an outcome of infection is associated with a diminished acute hepatitis that is temporally deficient for the expression of interferon gamma and tumor necrosis factor-alpha messenger RNAs. Hepatology 2001 33: 439 47.
42. Cote PJ, Toshkov I, Bellezza C et al. Temporal pathogenesis of experimental neonatal woodchuck hepatitis virus infection: increased initial viral load and decreased severity of acute hepatitis during the development of chronic viral infection. Hepatology 2000 32: 807 17.
43. Coffin CS, Michalak TI. Persistence of infectious hepadnavirus in the offspring of woodchuck mothers recovered from viral hepatitis. J. Clin. Invest. 1999 104: 203 12.
44. Lew YY, Michalak TI. In vitro and in vivo infectivity and pathogenicity of the lymphoid cell-derived woodchuck hepatitis virus. J. Virol. 2001 75: 1770 82.
45. Breiner KM, Schaller H, Knolle PA. Endothelial cell-mediated uptake of a hepatitis B virus: a new concept of liver targeting of hepatotropic microorganisms. Hepatology 2001 34: 803 8.
46. Vilarinho S, Ogasawara K, Nishimura S, Lanier LL, Baron JL. Blockade of NKG2D on NKT cells prevents hepatitis and the acute immune response to hepatitis B virus. Proc. Natl Acad. Sci. USA 2007 104: 18187 92.
47. Yang PL, Althage A, Chung J, Chisari FV. Hydrodynamic injection of viral DNA: a mouse model of acute hepatitis B virus infection. Proc. Natl Acad. Sci. USA 2002 99: 13825 30.
48. Kakimi K, Guidotti LG, Koezuka Y, Chisari FV. Natural killer T cell activation inhibits hepatitis B virus replication in vivo. J. Exp. Med. 2000 192: 921 30.
49. Kakimi K, Lane TE, Chisari FV, Guidotti LG. Cutting edge: Inhibition of hepatitis B virus replication by activated NK T cells does not require inflammatory cell recruitment to the liver. J. Immunol. 2001 167: 6701 5.
50. Bendelac A, Rivera MN, Park SH, Roark JH. Mouse CD1-specific NK1 T cells: development, specificity, and function. Annu. Rev. Immunol. 1997 15: 535 62.
51. de Lalla C, Galli G, Aldrighetti L et al. Production of profibrotic cytokines by invariant NKT cells characterizes cirrhosis progression in chronic viral hepatitis. J. Immunol. 2004 173: 1417 25.
52. Menne S, Roneker CA, Roggendorf M, Gerin JL, Cote PJ, Tennant BC. Deficiencies in the acute-phase cell-mediated immune response to viral antigens are associated with development of chronic woodchuck hepatitis virus infection following neonatal inoculation. J. Virol. 2002 76: 1769 80.
53. Bocharov G, Ludewig B, Bertoletti A et al. Underwhelming the immune response: effect of slow virus growth on CD8(+)-T-Lymphocyte responses. J. Virol. 2004 78: 2247 54.
54. Wang J, Michalak TI. Inhibition by woodchuck hepatitis virus of class I major histocompatibility complex presentation on hepatocytes is mediated by virus envelope pre-S2 protein and can be reversed by treatment with gamma interferon. J. Virol. 2006 80: 8541 53.
55. Diefenbach A, Tomasello E, Lucas M et al. Selective associations with signaling proteins determine stimulatory versus costimulatory activity of NKG2D. Nat. Immunol. 2002 3: 1142 9.
56. Guidotti L, Chisari F. To kill or to cure: options in host defense against viral infection. Curr. Opin. Immunol. 1996 8: 478 83.
57. Alberti A, Diana S, Sculard GH, Eddleston AL, Williams R. Detection of a new antibody system reacting with Dane particles in hepatitis B virus infection. Br. Med. J. 1978 2: 1056 8.
58. Grady GF, Lee VA, Prince AM et al. Hepatitis B immune globulin for accidental exposures among medical personnel: final report of a multicenter controlled trial. J. Infect. Dis. 1978 138: 625 38.
59. Ferrari C, Penna A, Bertoletti A et al. Cellular immune response to hepatitis B virus encoded antigens in acute and chronic hepatitis B virus infection. J. Immunol. 1990 145: 3442 9.
60. Jung M, Spengler U, Schraut W et al. Hepatitis B virus antigen-specific T-cell activation in patients with acute and chronic hepatitis B. J. Hepatol. 1991 13: 310 17.
61. Penna A, Artini M, Cavalli A et al. Long-lasting memory T cell responses following self-limited acute hepatitis B. J. Clin. Invest. 1996 98: 1185 94.
62. Penna A, Del Prete G, Cavalli A et al. Predominant T-helper 1 cytokine profile of hepatitis B virus nucleocapsid-specific T cells in acute self-limited hepatitis B. Hepatology 1997 25: 1022 7.
63. Rehermann B, Fowler P, Sidney J et al. The cytotoxic T lymphocyte response to multiple hepatitis B virus polymerase epitopes during and after acute viral hepatitis. J. Exp. Med. 1995 181: 1047 58.
64. Penna A, Chisari FV, Bertoletti A et al. Cytotoxic T lymphocytes recognize an HLA-A2-restricted epitope within the hepatitis B virus nucleocapsid antigen. J. Exp. Med. 1991 174: 1565 70.
65. Jung M, Hartmann B, Gerlach J et al. Virus-specific lymphokine production differs quantitatively but not qualitatively in acute and chronic hepatitis B infection. Virology 1999 261: 165 72.
66. Maini MK, Boni C, Ogg GS et al. Direct ex vivo analysis of hepatitis B virus-specific CD8+ T cells associated with the control of infection. Gastroenterology 1999 117: 1386 96.
67. Sobao Y, Tomiyama H, Sugi K et al. The role of hepatitis B virus-specific memory CD8 T cells in the control of viral replication. J. Hepatol. 2002 36: 105 15.
68. Webster GJ, Reignat S, Brown D et al. Longitudinal analysis of CD8+ T cells specific for structural and nonstructural hepatitis B virus proteins in patients with chronic hepatitis B: implications for immunotherapy. J. Virol. 2004 78: 5707 19.
69. Chang JJ, Wightman F, Bartholomeusz A et al. Reduced hepatitis B virus (HBV) -specific CD4+ T-cell responses in human immunodeficiency virus type 1-HBV-coinfected individuals receiving HBV-active antiretroviral therapy. J. Virol. 2005 79: 3038 51.
70. Boni C, Fisicaro P, Valdatta C et al. Characterization of hepatitis B virus (HBV)-specific T-cell dysfunction in chronic HBV infection. J. Virol. 2007 81: 4215 25.
71. Urbani S, Boni C, Amadei B et al. Acute phase HBV-specific T cell responses associated with HBV persistence after HBV/HCV coinfection. Hepatology 2005 41: 826 31.
72. Thursz M, Thomas H, Greenwood B, Hill A. Heterozygote advantage for HLA-class II type in hepatitis B virus infection. Nat. Genet. 1997 17: 11 12.
73. Thio CL, Thomas DL, Karacki P et al. Comprehensive analysis of class I and class II HLA antigens and chronic hepatitis B virus infection. J. Virol. 2003 77: 12083 7.
74. Kalams SA, Walker BD. The critical need for CD4 help in maintaining effective cytotoxic T lymphocyte responses. J. Exp. Med. 1998 188: 2199 204.
75. Ciurea A, Hunziker L, Klenerman P, Hengartner H, Zinkernagel RM. Impairment of CD4(+) T cell responses during chronic virus infection prevents neutralizing antibody responses against virus escape mutants. J. Exp. Med. 2001 193: 297 305.
76. Wherry EJ, Blattman JN, Murali-Krishna K, van der Most R, Ahmed R. Viral persistence alters CD8 T-cell immunodominance and tissue distribution and results in distinct stages of functional impairment. J. Virol. 2003 77: 4911 27.
77. Zhou S, Ou R, Huang L, Price GE, Moskophidis D. Differential tissue-specific regulation of antiviral CD8+ T-cell immune responses during chronic viral infection. J. Virol. 2004 78: 3578 600.
78. Rigopoulou EI, Suri D, Chokshi S et al. Lamivudine plus interleukin-12 combination therapy in chronic hepatitis B: antiviral and immunological activity. Hepatology 2005 42: 1028 36.
79. Boni C, Bertoletti A, Penna A et al. Lamivudine treatment can restore T cell responsiveness in chronic hepatitis B. J. Clin. Invest. 1998 102: 968 75.
80. Boni C, Penna A, Ogg G et al. Lamivudine treatment can overcome cytotoxic T cell hyporesponsiveness in chronic hepatitis B: new perspective for immune therapy. Hepatology 2001 33: 963 71.
81. Seeger C, Mason WS. Hepatitis B virus biology. Microbiol. Mol. Biol. Rev. 2000 64: 51 68.
82. Milich D, Chen M, Hughes J, Jones J. The secreted Hepatitis B precore antigen can modulate the immune response to the nucleocapsid: a mechanism for persistence. J. Immunol. 1998 160: 2013 21.
83. Milich D, Jones J, Hughes J, Price J, Raney A, McLachlan A. Is a function of the secreted hepatitis B e antigen to induce immunotolerance in vivo? Proc. Natl. Acad. Sci. USA 1990 87: 6599 603.
84. Milich D, Liang TJ. Exploring the biological basis of hepatitis B e antigen in hepatitis B virus infection. Hepatology 2003 38: 1075 86.
85. Chen MT, Billaud JN, Sallberg M et al. A function of the hepatitis B virus precore protein is to regulate the immune response to the core antigen. Proc. Natl. Acad. Sci. USA 2004 101: 14913 18.
86. Brunetto M, Giarin M, Oliveri F et al. Wild-type and e antigen-minus hepatitis B viruses and course of chronic hepatitis. Proc. Natl. Acad. Sci. USA 1991 88: 4186 90.
87. van Driel I, Ang D. The role of regulatory T cells in gastrointestinal inflammatory disease. J. Gastroenterol. Hepatol. 2008 23: 171 7.
88. Shevach EM. From vanilla to 28 flavors: multiple varieties of T regulatory cells. Immunity 2006 25: 195 201.
89. Li S, Gowans EJ, Chougnet C, Plebanski M, Dittmer U. Natural regulatory T cells and persistent viral infection. J. Virol. 2008 82: 21 30.
90. Manigold T, Racanelli V. T-cell regulation by CD4 regulatory T cells during hepatitis B and C virus infections: facts and controversies. Lancet Infect. Dis. 2007 7: 804 13.
91. Yang G, Liu A, Xie Q et al. Association of CD4+CD25+Foxp3+ regulatory T cells with chronic activity and viral clearance in patients with hepatitis B. Int. Immunol. 2007 19: 133 40.
92. Kondo Y, Kobayashi K, Ueno Y et al. Mechanism of T cell hyporesponsiveness to HBcAg is associated with regulatory T cells in chronic hepatitis B. World J. Gastroenterol. 2006 12: 4310 17.
93. Franzese O, Kennedy PT, Gehring AJ et al. Modulation of the CD8+-T-cell response by CD4+ CD25+ regulatory T cells in patients with hepatitis B virus infection. J. Virol. 2005 79: 3322 8.
94. Xu D, Fu J, Jin L et al. Circulating and liver resident CD4+CD25+ regulatory T cells actively influence the antiviral immune response and disease progression in patients with hepatitis B. J. Immunol. 2006 177: 739 47.
95. Stoop JN, van der Molen RG, Baan CC et al. Regulatory T cells contribute to the impaired immune response in patients with chronic hepatitis B virus infection. Hepatology 2005 41: 771 8.
96. Bauer T, Gunther M, Bienzle U, Neuhaus R, Jilg W. Vaccination against hepatitis B in liver transplant recipients: pilot analysis of cellular immune response shows evidence of HBsAg-specific regulatory T cells. Liver Transpl. 2007 13: 434 42.
97. Banchereau J, Briere F, Caux C et al. Immunobiology of dendritic cells. Annu. Rev. Immunol. 2000 18: 767 811.
98. Tavakoli S, Schwerin W, Rohwer A et al. Phenotype and function of monocyte derived dendritic cells in chronic hepatitis B virus infection. J. Gen. Virol. 2004 85: 2829 36.
99. Untergasser A, Zedler U, Langenkamp A et al. Dendritic cells take up viral antigens but do not support the early steps of hepatitis B virus infection. Hepatology 2006 43: 539 47.
100. Wang FS, Xing LH, Liu MX et al. Dysfunction of peripheral blood dendritic cells from patients with chronic hepatitis B virus infection. World J. Gastroenterol. 2001 7: 537 41.
101. Beckebaum S, Cicinnati VR, Dworacki G et al. Reduction in the circulating pDC1/pDC2 ratio and impaired function of ex vivo-generated DC1 in chronic hepatitis B infection. Clin. Immunol. 2002 104: 138 50.
102. Lohr HF, Pingel S, Bocher WO, Bernhard H, Herzog-Hauff S, Rose-John S. Reduced virus specific T helper cell induction by autologous dendritic cells in patients with chronic hepatitis B - restoration by exogenous interleukin-12. Clin. Exp. Immunol. 2002 130: 107 14.
103. van der Molen RG, Sprengers D, Binda RS et al. Functional impairment of myeloid and plasmacytoid dendritic cells of patients with chronic hepatitis B. Hepatology 2004 40: 738 46.
104. Chen M, Li YG, Zhang DZ et al. Therapeutic effect of autologous dendritic cell vaccine on patients with chronic hepatitis B: a clinical study. World J. Gastroenterol. 2005 11: 1806 8.
105. Fazle Akbar SM, Furukawa S, Yoshida O, Hiasa Y, Horiike N, Onji M. Induction of anti-HBs in HB vaccine nonresponders in vivo by hepatitis B surface antigen-pulsed blood dendritic cells. J. Hepatol. 2007 47: 60 6.
106. Barber DL, Wherry EJ, Masopust D et al. Restoring function in exhausted CD8 T cells during chronic viral infection. Nature 2006 439: 682 7.
107. Maier H, Isogawa M, Freeman GJ, Chisari FV. PD-1:PD-L1 interactions contribute to the functional suppression of virus-specific CD8+ T lymphocytes in the liver. J. Immunol. 2007 178: 2714 20.
108. Boettler T, Panther E, Bengsch B et al. Expression of the interleukin-7 receptor alpha chain (CD127) on virus-specific CD8+ T cells identifies functionally and phenotypically defined memory T cells during acute resolving hepatitis B virus infection. J. Virol. 2006 80: 3532 40.
109. Chen L, Zhang Z, Chen W et al. B7-H1 up-regulation on myeloid dendritic cells significantly suppresses T cell immune function in patients with chronic hepatitis B. J. Immunol. 2007 178: 6634 41.
110. Lucas M, Vargas-Cuero AL, Lauer GM et al. Pervasive influence of hepatitis C virus on the phenotype of antiviral CD8+ T cells. J. Immunol. 2004 172: 1744 53.
111. Ni YH, Huang LM, Chang MH et al. Two decades of universal hepatitis B vaccination in taiwan: impact and implication for future strategies. Gastroenterology 2007 132: 1287 93.
112. Adkins B, Leclerc C, Marshall-Clarke S. Neonatal adaptive immunity comes of age. Nat. Rev. Immunol. 2004 4: 553 64.
113. Thursz M. Genetic susceptibility in chronic viral hepatitis. Antiviral. Res. 2001 52: 113 16.
114. McMichael A, Klenerman P. HIV/AIDS. HLA leaves its footprints on HIV. Science 2002 296: 1410 11.
115. Sette A, Sidney J. Nine major HLA class I supertypes account for the vast preponderance of HLA-A and -B polymorphism. Immunogenetics 1999 50: 201 12.
116. Bertoni R, Sidney J, Fowler P, Chesnut R, Chisari F, Sette A. Human Histocompatibility Leukocyte Antigen-binding Supermotifs predict broadly cross-reactive Cytotoxic T lymphocyte responses in patients with acute hepatitis. J. Clin. Invest. 1997 100: 503 13.
117. Barouch D, Friede T, Stevanovic S et al. HLA-A2 subtypes are functionally distinct in peptide binding and presentation. J. Exp. Med. 1995 182: 1847 56.
118. Sudo T, Kamikawaji N, Kimura A et al. Differences in MHC class I self peptide repertoires among HLA-A2 subtypes. J. Immunol. 1995 155: 4749 56.
119. Leslie A, Price DA, Mkhize P et al. Differential selection pressure exerted on HIV by CTL targeting identical epitopes but restricted by distinct HLA alleles from the same HLA supertype. J. Immunol. 2006 177: 4699 708.
120. Middleton D, Menchaca L, Rood H, Komerofsky R. New allele frequency database: http://www.allelefrequencies.net. Tissue Antigens 2003 61: 403 7.
121. Bertoletti A, SEtte A, Chisari FV et al. Natural variants of cytotoxic epitopes are T-cell receptor antagonists for antiviral cytotoxic T cells. Nature 1994 369: 407 10.
122. Bertoletti A, Costanzo A, Chisari FV et al. Cytotoxic T lymphocyte response to a wild type hepatitis B virus epitope in patients chronically infected by variant viruses carrying substitutions within the epitope. J. Exp. Med. 1994 180: 933 43.
123. Seifert U, Liermann H, Racanelli V et al. Hepatitis C virus mutation affects proteasomal epitope processing. J. Clin. Invest. 2004 114: 250 9.
124. Sobao Y, Sugi K, Tomiyama H et al. Identification of hepatitis B virus-specific CTL epitopes presented by HLA-A*2402, the most common HLA class I allele in East Asia. J. Hepatol. 2001 34: 922 9.
125. Tsai SL, Chen MH, Yeh CT et al. Purification and characterization of a naturally processed hepatitis B virus peptide recognized by CD8+ cytotoxic T lymphocytes. J. Clin. Invest. 1996 97: 577 84.
126. Hwang YK, Kim NK, Park JM et al. HLA-A2 1 restricted peptides from the HBx antigen induce specific CTL responses in vitro and in vivo. Vaccine 2002 20: 3770 7.
127. Maini M, Bertoletti A. The Effects of Pathogens on the Immune System: Viral Hepatitis. Weinheim: Wiley-VCH, 2006.
128. Boni C, Penna A, Bertoletti A et al. Transient restoration of anti-viral T cell responses induced by lamivudine therapy in chronic hepatitis B. J. Hepatol. 2003 39: 595 605.
129. Depla E, Van der Aa A, Livingston B et al. Rational design of a multiepitope vaccine encoding T-lymphocyte epitopes for treatment of chronic Hepatitis B virus infections. J. Virol. 2008 82: 435 50.